This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients (AMBIDEX)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Fovea.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Gilead Sciences
Information provided by:
Fovea
ClinicalTrials.gov Identifier:
NCT00697944
First received: June 12, 2008
Last updated: June 13, 2008
Last verified: March 2009
  Purpose

To assess the safety of Ambisome 10 mg/kg/week in patients as a preemptive treatment in intensive care patients with a sepsis and rising candida colonisation.

Preemptive treatment (i.e., prophylactic treatment with two high doses of Ambisome® administered with an interval of one week, in patiens with a high risk of developing a fungal infection) should decrease the incidence of actual systemic infections.

The incidence of such actual fungal infections will be assessed directly and its impact on patients' survival and intensive care resourches assessed


Condition Intervention Phase
Sepsis Candida Drug: Amphotericine in liposome (Ambisome®) Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis

Resource links provided by NLM:


Further study details as provided by Fovea:

Primary Outcome Measures:
  • Global assessment of severity of adverse events; incidence, severity and consequences of treatment emergent effects [ Time Frame: 28−day observation period ]

Secondary Outcome Measures:
  • Duration of stay in the intensive care unit; occurrence of a systemic fungal infection [ Time Frame: 28 days after first treatment administration ]

Estimated Enrollment: 30
Study Start Date: March 2008
Estimated Study Completion Date: March 2009
Estimated Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Amphotericine in liposome (Ambisome®)
    2 IV infusions separated by one week 10 mg/kg per injection
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Supportive mechanical ventilation for more than 48 h
  • LOD > 5 with with ailing body systems
  • Candida colonisation of at least one site in addition to the digestive tract
  • Suspected nosocomial infection with antibiotic treatment
  • Informed consent

Exclusion Criteria:

  • Patients treated with oral or systemic antifungal agents within 15 days prior to inclusion
  • Patients requiring treatment with an antifungal agent or with a documented (proven or probable) fungal infection according to the EORTC criteria
  • Patients with a SAPS score > 65
  • Patients with neutropenia of that underwent a bone marrow tar organ transplant or with cancer chemotherapy

    • Blood creatinine > 220 µmol/L
  • Hemodyalysis
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00697944

Contacts
Contact: Jean−François RI DREYFUS, MD PhD 33-61-282-6780 jfdreyfus@aol.com

Locations
France
Chu Michallon Recruiting
Grenoble, France, 38000
Contact: TIMSIT       jftimsit@chu-grenoble.fr   
Hopital Saint Louis Not yet recruiting
Paris, France, 75010
Sponsors and Collaborators
Fovea
Gilead Sciences
Investigators
Principal Investigator: Elie AZOULAY, MD PhD University Teaching Hospital Saint Louis, Paris
  More Information

Responsible Party: DREYFUS Medical director, FOVEA
ClinicalTrials.gov Identifier: NCT00697944     History of Changes
Other Study ID Numbers: AMBIDEX
EUDRA−CT 2007−004444−71
Study First Received: June 12, 2008
Last Updated: June 13, 2008

Keywords provided by Fovea:
FUNGAL INFECTION
SEPSIS
INTENSIVE CARE
AMBISOME
PREEMPTIVE TREATMENT
Sepsis with candida colonisation

Additional relevant MeSH terms:
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Liposomal amphotericin B
Amphotericin B
Antifungal Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Amebicides
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on August 23, 2017